Postmenopausal osteoporosis: Current treatments;Ostéoporose postménopausique: Les traitements actuels

Revue de Medecine Interne

Volumn 25, Issue SUPPL. 5, 2004, Pages

  Roux, C ^a  

^a Institut Cochin   (France)

Author keywords

Bisphosphonate; Fracture; Hormone replacement therapy; Osteoporosis; SERM

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; CLODRONIC ACID; CONJUGATED ESTROGEN PLUS MEDROXYPROGESTERONE ACETATE; ETIDRONIC ACID; IBANDRONIC ACID; MEVALONIC ACID; PYROPHOSPHORIC ACID DERIVATIVE; RALOXIFENE; RISEDRONIC ACID; SELECTIVE ESTROGEN RECEPTOR MODULATOR; VITAMIN D; ZOLEDRONIC ACID;

ARTICLE; BONE DENSITY; EXERCISE; FRAGILITY FRACTURE; HORMONE SUBSTITUTION; HUMAN; POSTMENOPAUSE; POSTMENOPAUSE OSTEOPOROSIS; RISK FACTOR;

EID: 14844291591     PISSN: 02488663     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0248-8663(04)80056-0     Document Type: Article

References (26)

1. Anonyme Optimal calcium intake. NIH Consensus Development Panel on optimal calcmium intake JAMA 272 1994 1942 1948
2. Looker A.C., Harris T.B., Madans J.H., and Sempos C.T. Dietary calcium and hip fracture risk: the NHAMES I epidemiologic follow-up study Osteoprosis Int, 3 1993 177 184
3. Dawson Hughes B., Dallal G.E., Krall E.A., Sadowski L., Sahyoun N., and Tannenbaum S. A controlled trial of the effect of calcium supplementation on bone density in post menopausal women N Engl J Med 323 1990 878 883
4. Dawson Hughes B., Harris S.S., Krall E.A., and Dallal G.E. Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older N Engl J Med 337 1997 670 676
5. Ferrari S., Rizzoli R., Chevalley T., Slosman D., Eisman J.A., and Bonjour J.P. Vitamin D receptor gene polymorphisms and change in lumbar spine mineral density Lancet 345 1995 423 424
6. Chapuy M.C., Arlot M.E., Dubœuf F., Brun J., Crouzet B., and Arnaud S. Vitamin D3 and calcium to prevent hip fractures in elderly women N Engl J Med 327 1992 1637 1642
7. Lips P., Graafmans W.C., Ooms M.E., Bezmer D., and Bouter L.X. Vitamin D supplementation and fracture incidence in elderly persons: a randomized, placebo-controlled trial Ann Intern Med 124 1996 400 406
8. Province M.A., Hadley E.C., Hombrook M.C., Lipitz L.A., Miller J.P., and Mulrow C.D. The effects of exercice on falls in elderly patients. A preplanned meta-analysis of the FICSIT trials JAMA 273 1995 1341 1347
9. Berard A., Bravo G., and Gauthier P. Meta-analysis of the effectiveness of physical activity for the prevention of bone loss in post menopausal women Osteoporosis int 7 1997 331 337
10. Kannus P., Parkkari J., Niemo S., Pasanen M., Palvanen M., and Jarvinen M. Prevention of hip fracture in elderly people with use of a hip protector N Engl J Med 243 2000 1506 1513
11. Hosking D., Chilvers Ed., Christiansen C., Ravn P., Wasnich R., and Ross P. Prevention of bone loss with alendronate in posmenopausal women under 60 years of age N Engl J Med 338 1998 485 492
12. Black D.M., Cummings S.R., Karpf D.B., Cauley J.A., Thompson D.E., and Nevitt M.C. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures Lancet 348 1996 1535 1541
13. Cummings S.R., Black D.M., Thompson D.E., Appelgate W.B., Barrett-Connor E., and Musliner T.A. Effect of alendronare on risk of fracture in women with bone density but without vertebral fracture: results from the Fracture Intervention Trial JAMA 280 1998 2077 2082
14. Schnitzer T., Bone H.G., Crepaldi G., Adami S., McClung M., and Kiel D. Therapeutic equivalence of alendronate 70 mg once weekly and alendronate 10 mg daily in the treatmeent of osteoporosis Aging 12 2000 1 12
15. Bone H.G., Hosking D., Devogelaer J.P., Tucci J.R., Emkey R.D., and Tonino R.P. Ten years experience with alendronate for osteoporosis in post menopausal women N Engl J Med 350 2004 1189 1199
16. Harris S.T., Watts N.B., Genant H.K., McKeever C.D., Hangartner T., and Keller M. Effects of risedronate treatment on vertebral and non vertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial JAMA 282 1999 1344 1352
17. Reginster J., Minne H.W., Sorensen O.H., Hooper M., Roux C., and Brandi M.L. Randomized trial on the effects of risedronate on vertebral fractures in women with established postmenopasual osteoprosis Osteoporosis Int 11 2000 83 91
18. Roux C., Seeman E., Eastell R., Adachi J., Jackson R.D., and Felsenberg D. Efficacy of risedronate on clinical vertebral fractures within six months Curr Med Res Opin 20 2004 433 439
19. Harrington J.T., Ste-Marie L.G., Brandi M.L., Civitelli R., Fardellone P., and Grauer A. Risedronate rapidly reduces the risk for nonvertebral fractures in women with postmenopausal osteoporosis Calcif Tissue Int 74 2004 129 135
20. Watts N.B., Josse R.G., Hamdy R.C., Hughes R.A., Manhart R.A., and Barton I. Risedronate prevents new vertebral fractures in post menopausal women at high risk J Clin Endocrinol Metab 88 2003 542 549
21. McClung M.R., Geusens P., Miller P.D., Zippel H., Bensen W.G., and Roux C. Effect of risedronate on the risk of hip fracture in elderly women N Engl J Med 344 2001 333 340
22. Sorensen O.H., Crawford G.M., Mulder H., Hosking D.J., Gennari C., and Mellstrom D. Long-term efficacy of risedronate: a 5-year placebo-controlled clinical experience Bone 32 2003 120 126
23. Delmas P.D., Bjamason N.H., Mitlak B.H., Ravoux A.C., Shah A.S., and Huster W.J. Effects of raloxifene on bone mineral density, serum cholesterol concentration and uterine endometrium in post menopausal women N Engl J Med 337 1997 1641 1647
24. Ettinger B., Black D.M., Mitlak B.H., Knickerbocker R.K., Nickelsen T., and Genant H.K. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinicaltrial JAMA 282 1999 637 645
25. Cummings S.R., Eckert S., Krueger K.A., Grady D., Powles T.J., and Cauley J.A. The effect of raloxifene on risk of breast cancer in post menopausal women: results from the MORE randomized trial JAMA 281 1999 2189 2197
26. Barrett-Connor E., Grady D., Sashegyi A., Anderson P.W., Cox D.A., and Hoszowski F. Raloxifene and cardiovascular events in osteoporotic postmenopausal women: four-year results from the MORE (Multiple Outcomes of Raloxifen Evaluation) randomized trial JAMA 287 2002 847 857